Replies to post #5936 on Talon Therapeutics Inc (fka TLON)

[operating_line]

Thanks for confirming the number of CVRs issued. I think the first milestone will be underwhelming. I am more interested to see if this can hit the higher levels.

Below are published studies from 2014 that could help towards an expanded label of Marqibo.

http://www.ncbi.nlm.nih.gov/pubmed/24252360

http://www.ncbi.nlm.nih.gov/pubmed/24417913

The last publication is particularly interesting and the main reason I invested in Talon Pharmaceuticals.

It was mentioned this month (first in the list of similar substances) in the "Expert Review of Anticancer Therapy"
http://www.ncbi.nlm.nih.gov/pubmed/26402250

Also, CASI Pharmaceuticals may show sales growth of Marqibo in China but I guess these would feed into Spectrums's numbers.